Davis Polk advised AstraZeneca PLC in connection with its SEC-registered shelf takedown of $850 million aggregate principal amount of 3.500% notes due 2023, $400 million aggregate…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
